Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

Hansoh Pharma shares head skyward after HKEX debut

Hansoh Pharma shares head skyward after HKEX debut

Six other new chemical entities are in the mid- to late-stage pipeline, including a third-generation EGFR inhibitor that could be a rival to AstraZeneca’s Tagrisso (osimertinib) in China ... and has been filed for EGFR-positive non-small cell lung

Latest news

  • Oncology drives AstraZeneca, Genzyme boosts Sanofi Oncology drives AstraZeneca, Genzyme boosts Sanofi

    Third generation EGFR inhibitor Tagrisso is now the company’s top-selling drug, bringing in sales of $630m in the first quarter, almost double what the lung cancer drug made during ... Its Merck &Co-partnered PARP inhibitor Lynparza, which has

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    combination with the latter’s EGFR inhibitor Tagrisso (osimertinib) and PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in a series of proof-of-concept trials in solid tumours. ... Following after is surufatinib, an inhibitor of VEGF, FGFR and CSF-1R

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    Undeterred, Pfizer ran a third trial called ARCHER 1050 that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib), although ... it got a green light for PARP inhibitor

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    expression and overall survival rates, casting a cloud over PD-L1 checkpoint inhibitor Imfinzi in this setting. ... patients who have progressed on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment.

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    Pfizer persisted with a third study that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib). ... The latter drug already dominates second-line treatment of

More from news
Approximately 1 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics